June 8 Quick Takes: Fundings for Ariceum, Synklino, Anagenex and Biospring 

HealthCap and EQT Life Sciences led the €25 million ($26.9 million) series A round that will launch Ariceum Therapeutics GmbH, a Berlin-based start-up developing clinical radiopharmaceutical therapy satoreotide to treat neuroendocrine cancers. Ipsen Group (Euronext:IPN; Pink:IPSEY) spun out the SSTR2-targeting peptide therapeutic in 2021. Pureos Ventures invested alongside the round’s two leaders; private equity firm EQT AB (SSE:EQT) acquired LSP last year.

CureVac N.V. (NASDAQ:CVAC) hired Myriam Mendila as chief development officer and plans to develop a new class of cancer vaccines by combining its own mRNA expertise with the genomics and bioinformatics antigen discovery capabilities of Frame Cancer Therapeutics B.V., which it is acquiring. The German biotech is paying €16 million ($17 million) up front, with another €16 million tied to two undisclosed milestones; all monies will be paid in CureVac shares. CureVac also hired Myriam Mendila as chief development officer, effective Feb 1, 2023. Mendila, who is oncology CMO at Novartis AG (SIX:NOVN; NYSE:NVS), succeeds Klaus Edvardsen, who is resigning on June 30 to return to Denmark. Ulrike Gnad-Vogt, SVP area head oncology, will be interim chief development officer. ...